No abstract

BACKGROUND: Anemia cases in pregnant women in Indonesia are still high because pregnant women do not routinely take iron supplements or often referred as Tablet Tambah Darah because of the side effects it causes. An alternative to this problem is the intravenous administration of iron sucrose. AIM: The purpose of this study was to determine differences in ferritin and hemoglobin (Hb) levels before and after administration of iron sucrose injection to pregnant women in the second or third trimester at Araskabu Public Health Center, Deli Serdang. METHODS: This is an analytical study with a Quasi-Experimental Pre-Post Design for Second or Third Trimester Pregnant Women at Araskabu Public Health Center, Deli Serdang which was carried out in April 2022 by blood sampling and administration of iron sucrose injection intravenously, and then blood sampling was repeated 14 days after the injection in May 2022. The subjects in this study were 25 pregnant women aged 20–40 years who had antenatal care selected using the Consecutive Sampling technique. The difference in the mean of ferritin and Hb was analyzed using the paired t-test if the data are normally distributed and the Wilcoxon test if the data are not normally distributed. The results were significant if p < 0.001. The Mann–Whitney and Kruskal–Wallis tests were used to examine the difference between two or more sample groups. The results of the analysis were significant if p < 0.050. RESULTS: The mean ferritin level before administration of iron sucrose injection to pregnant women in this study was 18.97 ± 8.284 g/L and the mean ferritin level after iron sucrose injection was 98.95 ± 18.878 g/L. The mean increase in ferritin levels after injection of iron sucrose was 79.97 ± 19.77 g/L. The mean Hb level before administration of iron sucrose injection to pregnant women in this study was 10.13 ± 0.386 g/dL and the mean Hb level after administration was 12.01 ± 0.723 g/dL. The mean increase in Hb levels after injection of iron sucrose was 1.88 ± 0.68 g/dL. CONCLUSIONS: Iron sucrose injection can significantly increase ferritin and Hb levels.

No abstract

BACKGROUND: Cardiovascular disease is the number one cause of death in women worldwide. Preeclampsia may be more than just risk factor for the development of cardiovascular disease later in life. Systematic reviews suggested approximately double the risk of ischemic heart disease, cerebrovascular incidents, and mortality of cardiovascular disease after preeclampsia. AIM: The aim of the study was to analyze the differences of cardiovascular risk later in life-based on atherogenic index plasma and Framingham risk score (FRS) in postpartum women with preeclampsia compared with normotensive women. METHODS: This is study a comparative analytic study with case–control design on 46 subjects, divided by 23 postpartum preeclampsia patients as a case sample subject and 23 postpartum with no history of hypertension as the control group. Subjects were examined for blood pressure, height, weight, and asked to fast for at least 8 h before blood lipid profile and glucose were examined with laboratory methods. Atherogenic index plasma and FRS were measured. Data were analyzed using SPSS version 25. p < 0.05 was considered significant. RESULTS: Based on the results, the study found significant differences between systolic and diastolic blood pressure in preeclampsia compared to the control group. Median systolic and diastolic blood pressure in the preeclampsia group compared to control group were 180 versus 110 in systolic blood pressure; 100 versus 80 in diastolic blood pressure with p < 0.000. Total cholesterol, low-density lipid, high-density lipoprotein, and triglycerides levels in preeclampsia were 218.38 ± 23.26 mg/dL, 128.60 ± 22.74 mg/dL, 38.60 ± 5.99 mg/dL, and 252.73 ± 47.16 mg/dL, respectively, with p < 0.05 and non-preeclampsia group were 143.0 ± 16.82 mg/dL, 69.17 ± 23.03 mg/dL, 51.73 ± 8.65 mg/dL, and 121.30 ± 14.65 mg/dL, respectively, with p < 0.05. Differences in plasma atherogenic index values can clearly be observed in the preeclampsia and control groups (p < 0.05). A similar interpretation was found in the FRS (p < 0.05). There was a significant positive correlation between age and body mass index with atherogenic index plasma and FRS in preeclamptic group. CONCLUSION: There was a significant difference in atherogenic index plasma and Framingham risk score of postpartum preeclampsia and normotensive women.

BACKGROUND: Menopausal symptoms can greatly affect a woman’s personal, social, and work life. Selenium functions as a cofactor for glutathione peroxidase and helps minimize oxidative damage through cellular metabolism in postmenopausal women when estradiol production decreases, antioxidant protection is lost and therefore oxidative stress is increased. AIM: The aim of the study was to evaluated effect of selenium supplementation on selenium levels based on menopausal complaints assessed by menopause-specific quality of life questionnaire (MENQOL). MATERIALS AND METHODS: This research is an analytical study with quasi-experimental pre-test and post-test one group only design. The research was conducted on all postmenopausal women in Medan who were aged >51-years-old and met inclusion and exclusion criteria. The research subjects underwent blood tests to assess serum selenium levels. If data were normally distributed, dependent T test will be used, while if data were not normally distributed, Wilcoxon test will be used. The analysis results were stated to be significant with p < 0.05. RESULTS: Mean selenium serum levels before selenium administration were 93.20 ± 17.253 μg/L which increased to 132.12 ± 19.866 μg/L after selenium administration. Comparison test results of selenium levels before and after administration found p = 0.000 (p < 0.05), which means there was a significant difference of selenium serum levels before and after selenium administration. Besides that, there were no significant scores difference in aspects of vasomotor disorders (p = 1.000 [p > 0.05]), psychosocial disorders (p = 0.090 [p > 0.05]), physical disorders (p = 0.323 [p > 0.05]), and sexual disorders (p = 0.959 [p > 0.05]) between before and after selenium administration. CONCLUSION: Total MENQOL scores and complaints based on aspects of vasomotor, psychosocial, physical, and sexual disturbances did not show statistically significant changes after administration selenium tablets 100 mcg/day for 7 days.